益肾健脾解毒汤灌肠治疗慢性肾功能不全的相关实验研究
|
摘要
目的:本文通过实验研究,探讨益肾健脾解毒汤灌肠治疗慢性肾功能不全(CRI)的疗效及作用机理,同时观察通过灌肠给药治疗慢性肾功能不全的优点,为益肾健脾、活血化瘀、泄浊解毒法治疗慢性肾功能不全提供理论依据。方方法:本实验以大鼠为实验对象,进行相关实验研究。结结果:经益肾健脾解毒汤治疗后的实验大鼠在肾功能、血生化和常规指标、血液流变学指标上与治疗前或与对照组比较均有差异(P<0.05,P<0.01)。经益肾健脾解毒汤治疗后的大鼠肾功能、血液流变学与对照组和模型组比较均有差异(P<0.05);与正常组比较无显著性差异,中药组与模型组比较肾功能不全大鼠实验前后肾功能均有明显差异(P<0.05)。结结论:1、益肾健脾解毒汤可改善CRI大鼠肾功能或延缓肾功能恶化;2、益肾健脾解毒汤可改善CRI大鼠的血液流变学;3、益肾健脾解毒汤可提高大鼠血红细胞数、血清总蛋白、白蛋白水平,改善贫血症状;4、益肾健脾解毒汤可增强CRI大鼠的免疫功能;5、益肾健脾解毒汤可改善CRI大鼠肾脏病理改变,延缓肾小球硬化及肾间质纤维化。
Chronic Renal Insufficiency(CRI) is also called Chronic Renal Failure(CRF). CRI is a clinical syndrome that because of renal units seriouslysuffered by a variety of reasons and glomerular filtration rate(G.F.R)sustaining declining, the excretion of body’s metabolic waste and theaccommodation of water electrolyte’s and acid base’s balance are disordered.The major of clinical symptoms of CRI are composed of graduallydeteriorating kidney, disturbance of lipid metabolism, hypoproteinemia,immunologic inadequacy, glomerular sclerosis, renal interstitial fibrosis. CRIbelongs to Dropsy, Shenfeng, NiDu, Longbi, Guange, Xulao and so on, in thefield of traditional Chinese medicine. This paper is to make a zoopery study onthe effect and mechanism that the mixture of Yishen Jianpi Jiedu treat CRI byclyster, and the advantages of this measure. The main purpose is to offertheoretical supports of CRI treated by Yishen Jianpi, Huoxue Huayu, XiezuoJiedu .
In the experimental, male Wistar rats were given 2% adenine for 4 weeksto making CRI model. The model were randomly divided into model group,oxyamylitectus aldehydum group, traditional medicine treated by clystergroup ,and nomal control group, each 12. Traditional medicine group wereclysised 2ml mixture daily, and oxyamylitectus aldehydum group were given2ml Oxystarch by gavage. Other groups were given equal normal saline bygavage everyday. Continue administration for 6 weeks. Usea nitrogen,creatinine, total serum protein, albumin, blood ion, carban dioxide combiningpower, hemoglobin, red cell count, blood rheology (BHV, BLV PV) andkidney pathological examination are as the detected guideline, and compare the changes in each group.
Test results show that :①The Yishen Jianpijiedu decoction can improveCRI rats renal function, and compared with the oxyamylitectus aldehydumgroup, there are significant differences (P<0.05). Compared with the normalcontrol group statistics, it have no differences (P>0.05).②The Yishen Jianpijiedu decoction can improve CRI rats blood clotting. After the treatment , thetraditional medicine group’s indicators in the blood rheology (BHV, BLV, PV)have dropped significantly. Compared with the oxyamylitectus aldehydumgroup, there are significant differences (P<0.05).③The Yishen Jianpijiedudecoction can improve plasma protein and red cell count. There are significantdifferences (P<0.05) compared with the oxyamylitectus aldehydum group.④The Yishen Jianpijiedu decoction can improve the immune cells in rats andstronger rats’immunity. The number of lymphocytes of the traditionalmedicine group are more than the oxyamylitectus aldehydum group, and thereare significant differences (P<0.05).⑤Pathologically , in the traditionalmedicine group the cells of glomerulus do not grow and swell renal tubulesarrange in ranks, in which there is a small amount of drug crystallization and alittle cast. Renal interstitium hardens unsignificantly.
From the experimental data we can see that : The Yishen Jianpi jiedudecoction can improve CRI rats renal function and blood rheology, canincrease the level of red cell count, hemoglobin, total serum protein andalbumin, can stronger rats,immunity, can improve the its kidney pathologicalchange, and delay glomerulosclerosis and renal interstitial fibrosis.
Prescriptions of rhubarb, Salvia miltiorrhiza ,Astragalus, Chuanxiong byreducing intestinal absorption of the raw materials amino acid that synthesizethe urea, increase the concentration of essential amino acids in the blood, anduse its to synthesize protein. Liver and kidney reduce the synthesis of urea and inhibit of protein decomposition in vivo. Thereby, they can reduce urea andcreatinine in the source and improve CRI azotemia.
Prescriptions of Salvia miltiorrhiza, Chuanxiong, Sanqi, Spatholobussuberectus, Astragalus, Rhubarb increase blood flow in the microcirculationand accelerate blood flow velocity by improving microcirculation, forbiddingthe release of vasoconstrictor factor and expanding micro artery. They canreinforce fiber protein solubility to inhibit platelet aggregation and coagulation.They also can resist free radical oxidation , reduce lipid peroxidation ofglomerular injuried , increase the activity of SOD and scavenge free radicals.At the same time, the herb can lower the level of Serum triglyceride ,cholesterol and plasma lipid peroxidation. So, They can improve CRIhemorheology.
Prescriptions of rhubarb, Chuanxiong, Sanqi, Salvia miltiorrhiza reduceglomerular mesangial cell proliferation, extracellular matrix deposition andimmune complexes deposited in the glomerular, and regulate the genetranscription of smooth muscle cells in the kidney and apoptosis in order toimprove CRI pathological changes in the kidney and delay glomerulosclerosisand renal interstitial fibrosis.
Prescriptions of Astragalus, Poria the rhizome of large headedatractylodes, Dangshen, Rehmannia glutinosa, Zexie, Cinnamon, Herbaepimedii enhance the immune function of CRI, through enhancing humoralimmune function, cell mediated immune function and non specific immunefunction.
Prescriptions of Rehmannia glutinosa, Astragalus, Chuanxiong, SuberectSpatholobus, Sanqi can improve renal anemia of CRI by promoting theproliferation of hematopoietic growth factors, regulating the increase of theprotein synthesis and the differentiation related gene expression of hematopoietic cell proliferation and differentiation , improving erythroidprogenitor cell proliferation and differentiation, enhancing immune acticalcells involved in regulating and controlling the proliferation and differentiationof hematopoietic cells, and promoting bone marrow micro environment andbone marrow stem cells to cell hyperplasia.
The Yishen Jianpi jiedu decoction perform the unique advantages of thetreatment of CRI through enema administration :①. The PH value of therectum is more moderate compared with stomach and small intestine. There isno destruction of drugs, so it can be avoided that drug which were destructedin the digestive tract by acid and digestive enzymes by the oral low the effectand reduce. At the same time, it can avoid or reduce the drug side effects, suchas gastric stimulation.②. Drug absorbed in the rectum directly, can avoid thedecomposition and destruction when the drug at the first pass liver by the oral,thereby it reduce drugs on liver toxicity or side effects. The drug can directlygo into a cycle of drug and increase the release and absorption. It promote thebiological availability.③. For unable or unwilling to swallow the drugpatients, especially the late CIR, rectal administration is a convenient andeffective way because that uremic toxins stimulate the gastrointestinal tractand most of the patients have the symptoms such as nausea, vomiting.
Chronic Renal Insufficiency(CRI) is also called Chronic Renal Failure(CRF). CRI is a clinical syndrome that because of renal units seriouslysuffered by a variety of reasons and glomerular filtration rate(G.F.R)sustaining declining, the excretion of body’s metabolic waste and theaccommodation of water electrolyte’s and acid base’s balance are disordered.The major of clinical symptoms of CRI are composed of graduallydeteriorating kidney, disturbance of lipid metabolism, hypoproteinemia,immunologic inadequacy, glomerular sclerosis, renal interstitial fibrosis. CRIbelongs to Dropsy, Shenfeng, NiDu, Longbi, Guange, Xulao and so on, in thefield of traditional Chinese medicine. This paper is to make a zoopery study onthe effect and mechanism that the mixture of Yishen Jianpi Jiedu treat CRI byclyster, and the advantages of this measure. The main purpose is to offertheoretical supports of CRI treated by Yishen Jianpi, Huoxue Huayu, XiezuoJiedu .
In the experimental, male Wistar rats were given 2% adenine for 4 weeksto making CRI model. The model were randomly divided into model group,oxyamylitectus aldehydum group, traditional medicine treated by clystergroup ,and nomal control group, each 12. Traditional medicine group wereclysised 2ml mixture daily, and oxyamylitectus aldehydum group were given2ml Oxystarch by gavage. Other groups were given equal normal saline bygavage everyday. Continue administration for 6 weeks. Usea nitrogen,creatinine, total serum protein, albumin, blood ion, carban dioxide combiningpower, hemoglobin, red cell count, blood rheology (BHV, BLV PV) andkidney pathological examination are as the detected guideline, and compare the changes in each group.
Test results show that :①The Yishen Jianpijiedu decoction can improveCRI rats renal function, and compared with the oxyamylitectus aldehydumgroup, there are significant differences (P<0.05). Compared with the normalcontrol group statistics, it have no differences (P>0.05).②The Yishen Jianpijiedu decoction can improve CRI rats blood clotting. After the treatment , thetraditional medicine group’s indicators in the blood rheology (BHV, BLV, PV)have dropped significantly. Compared with the oxyamylitectus aldehydumgroup, there are significant differences (P<0.05).③The Yishen Jianpijiedudecoction can improve plasma protein and red cell count. There are significantdifferences (P<0.05) compared with the oxyamylitectus aldehydum group.④The Yishen Jianpijiedu decoction can improve the immune cells in rats andstronger rats’immunity. The number of lymphocytes of the traditionalmedicine group are more than the oxyamylitectus aldehydum group, and thereare significant differences (P<0.05).⑤Pathologically , in the traditionalmedicine group the cells of glomerulus do not grow and swell renal tubulesarrange in ranks, in which there is a small amount of drug crystallization and alittle cast. Renal interstitium hardens unsignificantly.
From the experimental data we can see that : The Yishen Jianpi jiedudecoction can improve CRI rats renal function and blood rheology, canincrease the level of red cell count, hemoglobin, total serum protein andalbumin, can stronger rats,immunity, can improve the its kidney pathologicalchange, and delay glomerulosclerosis and renal interstitial fibrosis.
Prescriptions of rhubarb, Salvia miltiorrhiza ,Astragalus, Chuanxiong byreducing intestinal absorption of the raw materials amino acid that synthesizethe urea, increase the concentration of essential amino acids in the blood, anduse its to synthesize protein. Liver and kidney reduce the synthesis of urea and inhibit of protein decomposition in vivo. Thereby, they can reduce urea andcreatinine in the source and improve CRI azotemia.
Prescriptions of Salvia miltiorrhiza, Chuanxiong, Sanqi, Spatholobussuberectus, Astragalus, Rhubarb increase blood flow in the microcirculationand accelerate blood flow velocity by improving microcirculation, forbiddingthe release of vasoconstrictor factor and expanding micro artery. They canreinforce fiber protein solubility to inhibit platelet aggregation and coagulation.They also can resist free radical oxidation , reduce lipid peroxidation ofglomerular injuried , increase the activity of SOD and scavenge free radicals.At the same time, the herb can lower the level of Serum triglyceride ,cholesterol and plasma lipid peroxidation. So, They can improve CRIhemorheology.
Prescriptions of rhubarb, Chuanxiong, Sanqi, Salvia miltiorrhiza reduceglomerular mesangial cell proliferation, extracellular matrix deposition andimmune complexes deposited in the glomerular, and regulate the genetranscription of smooth muscle cells in the kidney and apoptosis in order toimprove CRI pathological changes in the kidney and delay glomerulosclerosisand renal interstitial fibrosis.
Prescriptions of Astragalus, Poria the rhizome of large headedatractylodes, Dangshen, Rehmannia glutinosa, Zexie, Cinnamon, Herbaepimedii enhance the immune function of CRI, through enhancing humoralimmune function, cell mediated immune function and non specific immunefunction.
Prescriptions of Rehmannia glutinosa, Astragalus, Chuanxiong, SuberectSpatholobus, Sanqi can improve renal anemia of CRI by promoting theproliferation of hematopoietic growth factors, regulating the increase of theprotein synthesis and the differentiation related gene expression of hematopoietic cell proliferation and differentiation , improving erythroidprogenitor cell proliferation and differentiation, enhancing immune acticalcells involved in regulating and controlling the proliferation and differentiationof hematopoietic cells, and promoting bone marrow micro environment andbone marrow stem cells to cell hyperplasia.
The Yishen Jianpi jiedu decoction perform the unique advantages of thetreatment of CRI through enema administration :①. The PH value of therectum is more moderate compared with stomach and small intestine. There isno destruction of drugs, so it can be avoided that drug which were destructedin the digestive tract by acid and digestive enzymes by the oral low the effectand reduce. At the same time, it can avoid or reduce the drug side effects, suchas gastric stimulation.②. Drug absorbed in the rectum directly, can avoid thedecomposition and destruction when the drug at the first pass liver by the oral,thereby it reduce drugs on liver toxicity or side effects. The drug can directlygo into a cycle of drug and increase the release and absorption. It promote thebiological availability.③. For unable or unwilling to swallow the drugpatients, especially the late CIR, rectal administration is a convenient andeffective way because that uremic toxins stimulate the gastrointestinal tractand most of the patients have the symptoms such as nausea, vomiting.
引文
[1] Apple G. Kidney Int ,1991 ,39 :169 183。
[2] Akmal M,Kasim SE ,Soliman AR ,Massry SG. Kidney Int ,1990 ,37 :854 858.
[3] Cheng AK,Paker CJ ,Ren K,et al .Kidney Int 1996 ,49:1360 1371.
[4] 程悦,郭东阳.脂质代谢紊乱与肾脏疾病研究进展[J],西南军医,2004,6(6 ):39 42.
[5] 徐岩,高廷霞,马瑞霞,等.脂质代谢紊乱与慢性肾功能衰竭[J].国外医学泌尿系统分册,2003,23(4):449 451.
[6] Attman PO, Samuelsson O ,Alaupovic P.Am J Kidney Dis,1993,21:573 579.
[7] Kodarna,Otarfi,Yamada,et a1.Involvement of MCP 1 and M CSF inglomerular foam cell formation in ExHC rats.Kidney Int 1999(71),174.
[8] Nishda oda Yorioka . Effect of lipoproteinson mesangial cellproliferation.Kidney Int 1999(56),51.
[9] Hyunsoon Lee,Bongcho Kim ,Youngsook Kim et al. Involvement ofoxidation in LDL induced collagen gene regulation in mesangialcells.Kidney Intemational,1996(50):1582 1596.
[10] Kraemer R.Pomerantz KB.Joseph Silnerstein J.et a1.Induction ofbasicfibroblast growth factory mRNA an d protein synthesis in smoothmuscle cells by cholesteryl ester enrichment and25 hydmxycholestero1.JBiol Chem 1993.268:8040 8045.
[11] Galle,Schneider,Hein1oth,et a1.LP(a)and LDL induce apoptosis inhum an endothelial cells and in rabbit aorta:Role of oxidativestress.Kidney intemational 1999(555).1450 1461.
[12] Ding,Goor,Ricardo.Oxidized LDL stimulates the expression of TGF βand fibronectin in hum an glomerular epithelial cells KidneyIntemationa1.1997(51)147 154.
[13] Razzaque,Taguehi.Role of glomerular epithelial cell derived heatshock protein 47 inexperimental lipid nephropathy , Kidneyintemationa1.1999(71):256 259
[14] 董德长.实用肾脏病学[M].上海:上海科学技术出版社,1999:759 766.
[15] Eddv,Elaine,Mcculloch.Interstifial inflammation and fibrosis in ratswith diet induced hypercholestemlemia KidneyInternationa1.1996(50).1139 1149.
[16] Ishiyanaa,Atarashi,Minami,et al. Role offree radicals in thepathogenesis of lipid induced glomerulosclerosis in rats.KidneyInt1999(55):1348 1358.
[17] 张国莹,傅鹏,袁伟杰,等.甘油三酯“肾毒性"研究进展[J].国外医学泌尿系统分册,2003,23(3):323.
[18] Lilova MI,Velkovski IG,Topalov IB.Pesliatr Nephrol,2000,15(1 2):74 78.
[19] Lynn EG,OK.Lini Exp Pharmacol Phisiol,1997,24:973 975.
[20] Yaha As ,Jiri F ,Alex BM. Kidney Int ,1988 ;33 :498 507.
[21] Yaoita E , Kazama T , Kawasaki K,et al . Virch Archi B[ Cellpathol ] ,1985,285 294.
[22] 何作云,王瑞兴.临床细胞流变学[M].重庆:重庆大学出版社,1997:296 297.
[23] 杨志蕃,郑红光,等.慢性肾功能不全病人纤溶活性、内皮素及D二聚体的临床观察[J].沈阳部队医药,2003,16(3):195 196.
[24] Hong SY, Yang DH.Fibrinolytic activity in endstage renaldisease.Nephron, 1993;63:188.
[25] 陈书芬 慢性肾功能衰竭者粒系、粒单系集落刺激因子水平的观察,天津医学杂志[J], 1999 ,27(8):487.
[26] Moser B , Roth G, Brunner M, et al . Aberrant T cell activationandheightened apoptotic turnover in end stage renal failure patients :a conrparative evaluation between non dialysis , haemodialysis , andperitoneal dialysis. Biochem Biophys Res Commun,2003,308(3) :581.
[27] 戴勇,孙文学,等.慢性肾功能不全患者树突状细胞表型和功能的变化[J].广东医学杂志,2004,(25) 6:34 36.
[28] 载勇,李富荣,等.慢性肾功能不全患者外周血Thl/Th2淋巴细胞平衡的研究[J].实用医学杂志,2002,18(1):36 37.
[29] 张薇,沈波,等.淋巴细胞凋亡与慢性肾衰免疫功能低下的关系[J].上海第二医科大学学报,2003,23(6):541 544.
[30] 傅文录.慢性肾衰中医多级辨证思想与方法[J].新中医,1999,31(6):19.
[31] 叶桂荣.肾移植护理现状[J].国外医学护理学分册,1996,15(5):200 201.
[32] Yokozaws T.et al. Animal model of adenine induced chronic renalfailure in rats.Nephron,1986,44:230 234.
[33] 周小舟,等.腺嘌呤所致大鼠CRF的机理研究[J].基础医学与临床,1997,17(1):54 57.
[34] Klahr S,et al.Nephrology vol 2,1998:1181 1191.
[35] Philips Fs,Thiersh JB,Bendic H A.Admine intoxineationin relation to in vivo formation and deposition of 2,8 dioxyadmine inrenal tubules.J Pharmacal Exp Ther 1990:104:2O 3O.
[36] Augustin AJ,et al.Intestinal,hepatic and renal production ofthiobarbituric acidreaction substances and myelopreoxidase activityafter temporary aortic occlusion and reperfusion .Life Sci.1991.49:961.
[37] 胡明昌.氧自由基:慢性肾功能不全的进展因子[J].国外医学泌尿分册,1993;9(2):71.
[38] 西冈圣夫.大黄的生物活性及其成分.国外医学 中医药分册[J],1986:8(3):27.
[39] 郑平东,横泽隆子等.大黄治疗氮质血症及其作用机制的探讨,上海中医药杂志[J],1985,(8):46.
[40] 杨如哲.生大黄在治疗肾病中应用和作用机理[J].中医杂志,1987,(7):61.
[41] 黎磊石,刘志红,等.大黄延缓慢性肾衰的临床和实验研究[J].中西医结合杂志,1991,11(7):392.
[42] 王辉,罗先钦.丹参酮Ⅱ A 磺酸钠注射液治疗慢性肾衰氮质血症期的临床研究[J].医学创新研究,2007;4(5):18 19.
[43] 杜玉琴,李爱军,等. 黄芪注射液治疗肾功能衰竭40例临床分析[J].河北医药,1999,21 (2):212.
[44] 孙林,易著文,等. 川芎嗪对人胚肾系膜细胞增殖的影响及其机理探讨[J].中国中西医结合杂志,1995,15:l34 136.
[45] Yoshisa Y,M,Akai Y,et al.Nephron,2001;88(1):24 29.
[46] Lilova MI,Velkovski IG,Topalov IB.Pesliatr Nephrol,2000;15(1 2):74 78.
[47] Hamano K,Iwano M,Akai Y,et al.Am J Kidney Dis,2002;39(4):695 705.
[48] 史举彤,杨文浩,等.丹参素对体外循环中血细胞的影响[J].山东医科大学学报,1991,29(3):237.
[49] 程彰华,楼亚平,等.丹参素对微循环障碍和血浆乳酸含量影响的实验研究[J].上海医科大学学报,1987,14(1):25.
[50] 洪馨,安穗卿,等.复方丹参滴丸中丹参素的药物动力学研究[J].中药新药与临床药理,2000,11(5):286.
[51] 许国忠,孙宝春,等.川芎嗪对血小板保护的研究[J],中华麻醉学杂志,1995,5:202 205.
[52] Sheu JR,Kan YC,Hung WC ,et a1.Mechanisms involved in theantiplatelet activity of TMP in human platelets.ThrombRes,1997,88(3):259 270.
[53] 白善信.慢性肾衰竭的中草药防治研究,中国中西医结合肾病杂志[J].2001,2(4):246 247.
[54] 郭自强,王硕仁,等.丹参素和川芎嗪对血管紧张素Ⅱ致心肌肥大相关基因的影响[J].中国中西医结合杂志,2005,25(4):342 344.
[55] 胡仲仪,邵世宏,等.养阴固肾活血片对肾脏细胞外基质影响的实验研究[J].中国中西医结合肾病杂志,2000,1(3):144 145.
[56] 许军,王阶,等.三七总皂苷干预血栓形成研究概况[J],云南中医中药杂志,2003,24(5):46 47
[57] 苏雅,赵益桂,等. 三七三醇苷对动物血小板功能及血栓形成的影响[J].中草药,1996,27(11):666.
[58] 张志萍,刘屏,等.鸡血藤对高脂血症大鼠血浆超氧化物歧化酶和脂质过氧化物的影响[J].中国药理学会通讯,2000,17(3):15.
[59] 孙维广,等.中药对老年性痴呆免疫系统改变的干预作用[J].中国中西医结合杂志,2001,21(9):716.
[60] 刘志强,等.黄芪注射液对早期糖尿病肾病患者血小板功能和血浆内皮素的影响[J].中国中西医结合杂志,2001,21(4):276.
[61] 李保华,王世荣.参芪地黄汤加味治疗慢性肾衰竭53例疗效观察[J].中国中西医结合肾病杂志,2004,4(12):729 730.
[62] 纪泽泉,黄翠雯,等.大黄酸对肾小球硬化肾皮质凋亡蛋白酶 3活性及细胞凋亡的影响[J].2005,85(26):1836 1841.
[63] 刘志红,黎磊石,胡伟新,等.大黄素对肾小球系膜细胞PCNA的影响[J].细胞生物学杂志,1993,15(4):174 176.
[64] 唐利龙,汪丽惠.川芎嗪对原代培养血管平滑肌细胞胶原基因表达的影响[J].中国中西医结合杂志,1995,15:666 669.
[65] 刘海燕,陈孝文,刘华锋,等.三七总苷对尿毒症血清诱导的人肾小管上皮细胞TGF β、CTGFT 基因表达和蛋白分泌的影响[J].中国药理学通报,2005,21(11):1366 1370.
[66] 李春香,张艳玲,顾连方.丹参对慢性肾衰竭大鼠肾脏细胞凋亡及Fas FasL表达的影响[J].中国中西医结合肾病杂志,2002,3(2):101 102.
[67] 孙延,涛孙琦.黄芪的药理作用研究[J].黑龙江医药,2007,20(3):256 257.
[68] 翟伟宇.茯苓多糖的药效学研究[J].齐齐哈尔医学院学报,2005,26(8):935 937.
[69] 付玲,等.茯苓研究的新进展[J].新疆中医药,2005,23(3):79 83.
[70] 胡晓蕾 ,胡迎利,等.白术及白术多糖对SD大鼠生长性能和免疫功能的影响[J].中国兽药杂志,2006,40(1):2 6.
[71] 黄泰康,等.党参水煎液及多糖的药理研究[J].中成药,1994,16(7):31 33.
[72] 于震,王军,等.地黄苷A对环磷酰胺致小鼠白细胞少症的影响[J].中草药,2001,32(11):1002 1004.
[73] 王军,于震,等.地黄苷A对“阴虚”及免疫功能低下小鼠的药理作用[J].中国药学杂志,2002,37(1):20 22.
[74] 尹春萍,吴继洲.泽泻及其活性成分免疫调节作用研究进展[J].中草药,2001,32(12):1132.
[75] 曾正渝.兰作平.肉桂的研究现状及应用进展[J].现代医药卫生.2007,23(1):59 60.
[76] 蒋淑君,等.糖皮质激素对HPAA的影响及仙灵脾的调整作用[J].滨州医学院学报,2004,(27)2:87 90.
[77] 牛效清,王振,等.仙灵脾对慢性肾衰患者细胞免疫功能的影响[J].黑龙江医药科学,2002,25(5):44.
[78] 孙劲秋,何学红.肾性贫血机制探述[J].辽宁中医学院学报,2005,7(5):515 517.
[79] 李更生,等.地黄化学成分与药理研究进展[J].国外医学中医中药分册,2004,26(2):74 79.
[80] 祝晓玲 ,等.黄芪注射液影响贫血小鼠粒单系、红系造血及作用机制的探讨[J].中国中西医急救杂志,2001,8(5):284 286.
[81] 王艳萍,等.川芎嗪药理作用的研究进展[J].药品评价,2006,3(2):144 147.
[82] 邓家刚,等.鸡血藤药效及作用机理研究进展[J].广西中医药,2006,29(6):1 3.
[83] 高瑞兰,等.三七皂甙对造血细胞GATA 1和GATA 2转录调控蛋白的诱导作用[J].中华血液病杂志,2004,25(5):281 284.
[1] 张天,陈以平.实用中医肾病学(M).上海:上海中医学院版社 1990.
[2] 杨崇华.祖国医学对尿毒症的认识初探[J].中医研究,1996,9(4):3
[3] 郭恩绵.慢性肾功能衰竭的中医诊断命名及辨证论治之我见[J].实用中医内科学杂志,1988,(2):162.
[4] 时振声.慢性肾功能不全的中医治疗体会[J].吉林中医杂志,1989,(5):5.
[5] 高峻钰.慢性肾功能衰竭中医证治进展[J].中医杂志,1995,36(9):562.
[6] 傅文录.慢性肾功能衰竭中医治则新论[J].新中医 l995(2):6.
[7] 孙万森,等.益肾降脂片治疗慢性肾功能衰竭的临床和实验研究[J].中国中医药科技,1996,3(5):11.
[8] 张佩青,等.补脾肾泻湿浊解毒活血法治疗慢性肾功能衰竭的临床研究[J].中国中医药科技,1994,1(1):9.
[9] 郭兆安.祛毒散治疗慢性肾功能衰竭31例临床观察[J].中国中西医结合杂志,1995.15(11):679.
[10] 魏练波,等.慢性肾功能衰竭并发症的中医治疗[J].中医杂志,1997,38(4):222.
[11] 彭建中,扬连柱.赵绍琴临证验案精选(M).北京:学苑出版杜,1996,208 220.
[12] 赵动,等.肾衰系列方治疗慢性肾功能衰竭的体会[J].中医杂志,1994,35(3):143.
[13] 王文春.化瘀解毒法治疗慢性肾炎肾功能衰竭的临床体会[J].河南中医,1994,(5):297.
[14] 邓乐巧.以三焦气化辨治慢性肾功能衰竭14例[J].云南中医杂志,1994,15(2):7.
[15] 傅晓骏.谈“瘀浊蕴毒”与慢性肾衰竭[J].中国中西医结合肾病杂志,2002,3(5):293.
[16] 沈庆法.慢性肾功能衰竭的中医认识和临床研究[J].上海中医药杂志,2000,34(3):42 44.
[17] 栾雷.慢性肾衰关乎少阳阳明[J].辽宁中医杂志,2005,32(2):112 l13.
[18] 刘丙欣.运用络病理论辨治慢性肾功能衰竭解析[J].中医药学刊,2005,23(3):505 506.
[19] 谢帮军,张军锋,石景亮.从三焦辨治肾病临床经验[J].四川中医,2005,23(2):1 2.
[20] 曾莉.洪钦国教授治疗慢性肾功能不全经验介绍[J].新中医,2006:38(4):13 14.
[21] 傅文录.慢性肾衰中医多级辨证思想与方法[J].新中医,1999,31(6):19.
[22] 王淑渡,等.保元强肾I号片对慢性肾功能衰竭血浆及尿SOD、MDA的影响[J].浙江中西医结合杂志,1997,7(2):67.
[23] 沈维增,李俊彪,伍新林,等.泄浊汤对慢性肾衰竭患者脂质代谢及肾功能的影响[J].中国中西医结合肾病杂志,2004,5(3):166 168.
[24] 刘延东,吴世杰.加减八珍汤治疗慢性肾功能衰竭40例疗效观察[J].中国中医药科技,2004,l1(3):178 179.
[25] 周富明.慢性肾衰辨治五法[J].浙江中医杂志,2005,2:74 75.
[26] 薛红等.杜仲补腰合剂改善慢性肾功能不全的实验研究[J].河北中医药学报,2004,19(3):1 4.
[27] 宁越峰,杨柳竹,等.加味八珍汤治疗慢性肾功能不全患者营养不良[J].中国煤炭工业医学杂志,2002,5(7):729.
[28] 朱玮华.温补脾肾、通阳泄浊法治疗慢性肾功能衰竭一得[J].中国临床医生,2006,34(4):47.
[29] 何灵芝. 补阳还五汤治疗肾病举隅[J].广西中医药,2005,28(6):34.
[30] 胡臻.升阳排毒汤治疗慢性肾功能不全疗效观察[J].浙江中西医结合杂志,2002,l2(8): 478.
[31] 朱洪丽.理脾法治疗慢性肾功能不全体会[J].实用中医药杂志,2004,20(11):655.
[32] 许钟镐.活血化瘀中药复方延缓慢性肾功能不全的实验研究[J]. 延边大学医学杂志, 2000 , 23(1): 44-46.
[33] 冯文学.大黄治疗慢性肾功能不全25例的疗效分析[J]. 河南医药信息 2000,2(8): 57.
[34] 刘学耀,洪钦国.尿毒清胶囊治疗45例慢性肾衰疗效分析[J].中医药学刊,2004,22(4):687 688.
[35] 李文红,王淑君.肾衰降浊丸治疗慢性肾功能不全50例[J].实用中医内科杂志,2005,19(2):165.
[36] 李贵明,常连刚,孙晓燕,等.黄虎肾衰散在慢性肾衰竭中的应用[J].中国中西医结合杂志,2005,6(1):48 49.
[37] 詹永力,等.和解法对延缓慢性肾功能衰竭病程进展的研究[J].中国中西医结合杂志,1995,15(2):71.
[38] 冯松杰.大黄鹰虫丸治疗血液透析患者脂质代谢异常22例[J].辽宁中医杂志,1996,23(8):368.
[39] 刘文军,等.中药尿毒净腔囊治疗慢性肾功能衰竭的近期疗效察[J].实用中西医结合杂志,1995(8):555.
[40] 刘慰祖,等.中医药对慢性肾功能衰竭患者脂质代谢的影响[J].上海中医药杂志,1995,(7):15.
[41] 夏海岩.扶正降浊汤为主治疗慢性肾功能不全30例[J].辽宁中医药学报,2000,,2(4)::292.
[42] 金翠萍.参芪地黄汤联合黄连温胆汤加生大黄治疗慢性肾功能不全3l例[J].华北煤炭医学院学报,2004:6(3):341.
[43] 吴兆东,朱海龙,王国斌,等.大黄廑虫丸联合金水宝胶囊治疗慢性肾功能衰竭53例[J].中国中医药信息杂志,2005,12(2):68 69.
[44] 胡筱娟.尿毒宝胶囊治疗慢性肾功能不全32例[J].陕西中医,2005,26(4):311 312.
[45] 程仁权.大黄在慢性肾衰中的应用[J ]. 中医药学报,1998,26 (6):49 50.
[46] 宁远英.大黄素对人肾成纤维细胞增殖的影响[J ]. 中西医结合杂志,2000,20 (2):105.
[47] 魏向阳.大黄延缓慢性肾功能衰竭机制的研究进展[J]. 现代中医药,2003,(3):58 59.
[48] 肖炜,邓虹珠,马云.大黄治疗慢性肾功能衰竭的临床与实验研究概述[J].中国中药杂志,,2002,27(4):241 242.
[49] 齐家友,王海燕,王叔咸.黄芪和当归治疗3种不同病理类型肾炎的实验研究[J].中华内科杂志,1996,35(4):222.
[50] 崔明姬, 徐学明.慢性肾功能不全患者血浆神经肽Y变化及黄芪对其影响的研究[J].白求恩医科大学学报,2001,27 (2):164 165.
[51] 周钦,陈雪梅,高渝军.大剂量黄芪对慢性肾功能不全患者血、尿降钙素基因相关肽的影响[J]. 北京中医药大学学报,,2000,23 (12):59 60.
[52] 王莹,李振华.黄芪对慢性肾功能不全患者抗氧化酶和一氧化氮的影响[J].哈尔滨医药,2002,22 (6):5 6.
[53] 王本祥.现代中药药理学(M).天津:天津科学技术出版社,1999:883 884.
[54] 李洪清,徐学明.丹参对慢性肾功能不全患者血清白细胞介素 6和肿瘤坏死因子的影响[J].临床内科杂志,2002,19 (6):470 471.
[55] 周晓萍,袁红玲.丹参注射液在慢性肾功能不全患者中的应用[J].职业与健康,2003,19 (4):135 136.
[56] 黄道勤,赖建生,夏强,等.丹参注射液保护肾缺血 再灌注损伤的实验研究[J]. 海南医学,2004,15 ( 7 ):116 114.
[57] 陈英.三七总苷的药理研究及临床应用进展[ J ]. 广西医学,1998,20 (6):1109 1112.
[58] 叶任高.内科学(M).北京:人民卫生出版社,2002,570.
[59] 杜军.三七止血活血机理研究Ⅰ:不同剂量的三七对小鼠凝血系统的作用[J ].中药药理与临床, 1995:111 (5):25 28.
[60] 陈江斌,许家璃,江洪,等.三七总皂苷对冠心病患者过氧化脂质及纤维蛋白溶酶原激活物的影响[J ].中国新药杂志, 2000, 9 (11):781 782.
[61] 周晓霞,苏佩清,杨鹤梅,等.三七总皂苷对人高脂血清诱发的胎儿血管平滑肌细胞增殖的抑制作用[J ]. 中国动脉硬化杂志,,2000,8(1):43 45.
[62] 曾青,陈吉球,黄勤等.三七总皂苷对血清及肺组织血管紧张素转换酶的影响[J ].广西医科大学学报,1998,15 (3):36 38.
[63] 韦颖,樊均明,潘丽萍.三七总苷对人肾成纤维细胞的影响[J ].中国中西医结合杂志,2002,22 (1):47 49.
[64] 王莉,王丽,万晓京,等.黄葵胶囊治疗慢性肾脏疾病的临床观察[J].中医药信息,2002,19 (1):36 37.
[65] 傅余芹.冬虫夏草制剂对慢性肾功能不全患者T细胞亚群的影响[J].深圳中西医结合杂志,2003,13 ( 1 ):21 26.
[66] 赵继红.百令胶囊对慢性肾功能不全患者脂代谢水平的影响[J].天津中医,2002,19 (5):9.
[67] 吕凤岩.包醛氧淀粉胶囊联合冬虫夏草制剂治疗慢性肾衰竭的临床观察[J].中国中西医结合肾病杂志,2004,5(9):525 526.
[68] 邓跃毅,陈以平,贺学林,等.冬虫夏草制剂延缓慢性肾衰竭的机理研究[J].中国中西医结合杂志,2001,2(7):381 383.
[69] 张盛光,熊国良,阳硗,等.益气补肾冲剂治疗慢性肾功不全的初步临床及实验研究[J].中国中西医结合杂志,l992:12(6):335.
[70] 张琪. 张琪临床经验辑要[M ]. 北京: 中国医药科技出版社,1999,80 80.
[71] 姜桂芹,韩学忠.归脾汤加减治疗慢性肾衰贫血的临证体会[J ]. 中国中西医结合肾病杂志,2003,4 (4):231 232.
[72] 孙万森,刘锐. 治疗慢性肾衰经验探要[J ]. 陕西中医,2000,(5) :212 213.
[73] 骆常义,龚去非.治疗慢性肾衰经验[J ]. 实用中医药杂志.2000,16(2):36 37.
[74] 朱冬云,蓝华生.治疗慢性肾衰经验[J ]. 河北中医,2000,22 (10):746 747.
[75] 姜桂芹,韩学忠.归脾汤加减治疗慢性肾衰贫血的临证体会[J ].中国中西医结合肾病杂志,2003,4 (4):231 232.
[76] 段淑兰,陈小仙,蒋鹏.中药为主治疗慢性肾功能不全40例临床观察[J]. 河南中医,2004,5 (24):36 37.
[77] 庞莉,张小斌,张渭.从瘀辨治慢性肾功能不全临床观察[J].现代中医药,2003,(1):31 32.
[78] 李淑菊,张佩青,黄彦彬,等.肾衰胶囊延缓失代偿期慢性肾功能衰竭进展39例临床观察[J].中医杂志,2005,46(5):348 350.
[79] 王少华,陈静,付强.肾衰胶囊对慢性肾功能衰竭大鼠细胞凋亡的影响[J].中药材,2004,27(3):195 197.
[80] 王少华,张晶瑜,张春梅.肾衰胶囊对肾衰大鼠肾功能及血NO、TNF2α的影响[J].中成药,2004,26(1):54 56.
[81] 张秀萍等. 尿毒清颗粒治疗慢性肾衰竭临床分析[J].中华现代中西医杂志.2005:3(18):1683 1684.
[82] 库保庆,高智.补阳还五汤治疗慢性肾衰竭的临床研究[J].临床肾病杂志.2007,7(2):74
[83] 郭兆安. 清氮汤灌肠治疗CRF43例[J].中国中西医结合志.1996,18(9):564.
[84] 来永兰,孙文芹,等. 祛浊温阳汤灌肠治疗慢性肾功能不全临床观察[J].中国中西医结合急救杂志,2003,10(4):247 248.
[85] 王其丽,张正勇.中药保留灌肠治疗肾功能不全56例疗效观察[J].中华中医药杂志,2005,20(8):511.
[86] 刘文合,施绍用,等. 中药灌肠治疗慢性肾功能不全疗效观察[J].中华医学实践志,2005,5(6):651 652.
[87] 张伟君,彭建华,等. 复方大黄汤灌肠治疗慢性肾功能不全临床疗效观察[J].中华现代中医学杂志,2006,2(3):215 216.
[88] 梁淼,胡亚丹,等. 中药保留灌肠治疗糖尿病肾病肾功能不全临床观察[J].实用中医内科杂志,2006,20(6):663.
[89] 王艳秋.灌肠治疗慢性肾功能不全32例疗效观察[J].局解手术学杂志,2007,16(3):188 189.
[2] Akmal M,Kasim SE ,Soliman AR ,Massry SG. Kidney Int ,1990 ,37 :854 858.
[3] Cheng AK,Paker CJ ,Ren K,et al .Kidney Int 1996 ,49:1360 1371.
[4] 程悦,郭东阳.脂质代谢紊乱与肾脏疾病研究进展[J],西南军医,2004,6(6 ):39 42.
[5] 徐岩,高廷霞,马瑞霞,等.脂质代谢紊乱与慢性肾功能衰竭[J].国外医学泌尿系统分册,2003,23(4):449 451.
[6] Attman PO, Samuelsson O ,Alaupovic P.Am J Kidney Dis,1993,21:573 579.
[7] Kodarna,Otarfi,Yamada,et a1.Involvement of MCP 1 and M CSF inglomerular foam cell formation in ExHC rats.Kidney Int 1999(71),174.
[8] Nishda oda Yorioka . Effect of lipoproteinson mesangial cellproliferation.Kidney Int 1999(56),51.
[9] Hyunsoon Lee,Bongcho Kim ,Youngsook Kim et al. Involvement ofoxidation in LDL induced collagen gene regulation in mesangialcells.Kidney Intemational,1996(50):1582 1596.
[10] Kraemer R.Pomerantz KB.Joseph Silnerstein J.et a1.Induction ofbasicfibroblast growth factory mRNA an d protein synthesis in smoothmuscle cells by cholesteryl ester enrichment and25 hydmxycholestero1.JBiol Chem 1993.268:8040 8045.
[11] Galle,Schneider,Hein1oth,et a1.LP(a)and LDL induce apoptosis inhum an endothelial cells and in rabbit aorta:Role of oxidativestress.Kidney intemational 1999(555).1450 1461.
[12] Ding,Goor,Ricardo.Oxidized LDL stimulates the expression of TGF βand fibronectin in hum an glomerular epithelial cells KidneyIntemationa1.1997(51)147 154.
[13] Razzaque,Taguehi.Role of glomerular epithelial cell derived heatshock protein 47 inexperimental lipid nephropathy , Kidneyintemationa1.1999(71):256 259
[14] 董德长.实用肾脏病学[M].上海:上海科学技术出版社,1999:759 766.
[15] Eddv,Elaine,Mcculloch.Interstifial inflammation and fibrosis in ratswith diet induced hypercholestemlemia KidneyInternationa1.1996(50).1139 1149.
[16] Ishiyanaa,Atarashi,Minami,et al. Role offree radicals in thepathogenesis of lipid induced glomerulosclerosis in rats.KidneyInt1999(55):1348 1358.
[17] 张国莹,傅鹏,袁伟杰,等.甘油三酯“肾毒性"研究进展[J].国外医学泌尿系统分册,2003,23(3):323.
[18] Lilova MI,Velkovski IG,Topalov IB.Pesliatr Nephrol,2000,15(1 2):74 78.
[19] Lynn EG,OK.Lini Exp Pharmacol Phisiol,1997,24:973 975.
[20] Yaha As ,Jiri F ,Alex BM. Kidney Int ,1988 ;33 :498 507.
[21] Yaoita E , Kazama T , Kawasaki K,et al . Virch Archi B[ Cellpathol ] ,1985,285 294.
[22] 何作云,王瑞兴.临床细胞流变学[M].重庆:重庆大学出版社,1997:296 297.
[23] 杨志蕃,郑红光,等.慢性肾功能不全病人纤溶活性、内皮素及D二聚体的临床观察[J].沈阳部队医药,2003,16(3):195 196.
[24] Hong SY, Yang DH.Fibrinolytic activity in endstage renaldisease.Nephron, 1993;63:188.
[25] 陈书芬 慢性肾功能衰竭者粒系、粒单系集落刺激因子水平的观察,天津医学杂志[J], 1999 ,27(8):487.
[26] Moser B , Roth G, Brunner M, et al . Aberrant T cell activationandheightened apoptotic turnover in end stage renal failure patients :a conrparative evaluation between non dialysis , haemodialysis , andperitoneal dialysis. Biochem Biophys Res Commun,2003,308(3) :581.
[27] 戴勇,孙文学,等.慢性肾功能不全患者树突状细胞表型和功能的变化[J].广东医学杂志,2004,(25) 6:34 36.
[28] 载勇,李富荣,等.慢性肾功能不全患者外周血Thl/Th2淋巴细胞平衡的研究[J].实用医学杂志,2002,18(1):36 37.
[29] 张薇,沈波,等.淋巴细胞凋亡与慢性肾衰免疫功能低下的关系[J].上海第二医科大学学报,2003,23(6):541 544.
[30] 傅文录.慢性肾衰中医多级辨证思想与方法[J].新中医,1999,31(6):19.
[31] 叶桂荣.肾移植护理现状[J].国外医学护理学分册,1996,15(5):200 201.
[32] Yokozaws T.et al. Animal model of adenine induced chronic renalfailure in rats.Nephron,1986,44:230 234.
[33] 周小舟,等.腺嘌呤所致大鼠CRF的机理研究[J].基础医学与临床,1997,17(1):54 57.
[34] Klahr S,et al.Nephrology vol 2,1998:1181 1191.
[35] Philips Fs,Thiersh JB,Bendic H A.Admine intoxineationin relation to in vivo formation and deposition of 2,8 dioxyadmine inrenal tubules.J Pharmacal Exp Ther 1990:104:2O 3O.
[36] Augustin AJ,et al.Intestinal,hepatic and renal production ofthiobarbituric acidreaction substances and myelopreoxidase activityafter temporary aortic occlusion and reperfusion .Life Sci.1991.49:961.
[37] 胡明昌.氧自由基:慢性肾功能不全的进展因子[J].国外医学泌尿分册,1993;9(2):71.
[38] 西冈圣夫.大黄的生物活性及其成分.国外医学 中医药分册[J],1986:8(3):27.
[39] 郑平东,横泽隆子等.大黄治疗氮质血症及其作用机制的探讨,上海中医药杂志[J],1985,(8):46.
[40] 杨如哲.生大黄在治疗肾病中应用和作用机理[J].中医杂志,1987,(7):61.
[41] 黎磊石,刘志红,等.大黄延缓慢性肾衰的临床和实验研究[J].中西医结合杂志,1991,11(7):392.
[42] 王辉,罗先钦.丹参酮Ⅱ A 磺酸钠注射液治疗慢性肾衰氮质血症期的临床研究[J].医学创新研究,2007;4(5):18 19.
[43] 杜玉琴,李爱军,等. 黄芪注射液治疗肾功能衰竭40例临床分析[J].河北医药,1999,21 (2):212.
[44] 孙林,易著文,等. 川芎嗪对人胚肾系膜细胞增殖的影响及其机理探讨[J].中国中西医结合杂志,1995,15:l34 136.
[45] Yoshisa Y,M,Akai Y,et al.Nephron,2001;88(1):24 29.
[46] Lilova MI,Velkovski IG,Topalov IB.Pesliatr Nephrol,2000;15(1 2):74 78.
[47] Hamano K,Iwano M,Akai Y,et al.Am J Kidney Dis,2002;39(4):695 705.
[48] 史举彤,杨文浩,等.丹参素对体外循环中血细胞的影响[J].山东医科大学学报,1991,29(3):237.
[49] 程彰华,楼亚平,等.丹参素对微循环障碍和血浆乳酸含量影响的实验研究[J].上海医科大学学报,1987,14(1):25.
[50] 洪馨,安穗卿,等.复方丹参滴丸中丹参素的药物动力学研究[J].中药新药与临床药理,2000,11(5):286.
[51] 许国忠,孙宝春,等.川芎嗪对血小板保护的研究[J],中华麻醉学杂志,1995,5:202 205.
[52] Sheu JR,Kan YC,Hung WC ,et a1.Mechanisms involved in theantiplatelet activity of TMP in human platelets.ThrombRes,1997,88(3):259 270.
[53] 白善信.慢性肾衰竭的中草药防治研究,中国中西医结合肾病杂志[J].2001,2(4):246 247.
[54] 郭自强,王硕仁,等.丹参素和川芎嗪对血管紧张素Ⅱ致心肌肥大相关基因的影响[J].中国中西医结合杂志,2005,25(4):342 344.
[55] 胡仲仪,邵世宏,等.养阴固肾活血片对肾脏细胞外基质影响的实验研究[J].中国中西医结合肾病杂志,2000,1(3):144 145.
[56] 许军,王阶,等.三七总皂苷干预血栓形成研究概况[J],云南中医中药杂志,2003,24(5):46 47
[57] 苏雅,赵益桂,等. 三七三醇苷对动物血小板功能及血栓形成的影响[J].中草药,1996,27(11):666.
[58] 张志萍,刘屏,等.鸡血藤对高脂血症大鼠血浆超氧化物歧化酶和脂质过氧化物的影响[J].中国药理学会通讯,2000,17(3):15.
[59] 孙维广,等.中药对老年性痴呆免疫系统改变的干预作用[J].中国中西医结合杂志,2001,21(9):716.
[60] 刘志强,等.黄芪注射液对早期糖尿病肾病患者血小板功能和血浆内皮素的影响[J].中国中西医结合杂志,2001,21(4):276.
[61] 李保华,王世荣.参芪地黄汤加味治疗慢性肾衰竭53例疗效观察[J].中国中西医结合肾病杂志,2004,4(12):729 730.
[62] 纪泽泉,黄翠雯,等.大黄酸对肾小球硬化肾皮质凋亡蛋白酶 3活性及细胞凋亡的影响[J].2005,85(26):1836 1841.
[63] 刘志红,黎磊石,胡伟新,等.大黄素对肾小球系膜细胞PCNA的影响[J].细胞生物学杂志,1993,15(4):174 176.
[64] 唐利龙,汪丽惠.川芎嗪对原代培养血管平滑肌细胞胶原基因表达的影响[J].中国中西医结合杂志,1995,15:666 669.
[65] 刘海燕,陈孝文,刘华锋,等.三七总苷对尿毒症血清诱导的人肾小管上皮细胞TGF β、CTGFT 基因表达和蛋白分泌的影响[J].中国药理学通报,2005,21(11):1366 1370.
[66] 李春香,张艳玲,顾连方.丹参对慢性肾衰竭大鼠肾脏细胞凋亡及Fas FasL表达的影响[J].中国中西医结合肾病杂志,2002,3(2):101 102.
[67] 孙延,涛孙琦.黄芪的药理作用研究[J].黑龙江医药,2007,20(3):256 257.
[68] 翟伟宇.茯苓多糖的药效学研究[J].齐齐哈尔医学院学报,2005,26(8):935 937.
[69] 付玲,等.茯苓研究的新进展[J].新疆中医药,2005,23(3):79 83.
[70] 胡晓蕾 ,胡迎利,等.白术及白术多糖对SD大鼠生长性能和免疫功能的影响[J].中国兽药杂志,2006,40(1):2 6.
[71] 黄泰康,等.党参水煎液及多糖的药理研究[J].中成药,1994,16(7):31 33.
[72] 于震,王军,等.地黄苷A对环磷酰胺致小鼠白细胞少症的影响[J].中草药,2001,32(11):1002 1004.
[73] 王军,于震,等.地黄苷A对“阴虚”及免疫功能低下小鼠的药理作用[J].中国药学杂志,2002,37(1):20 22.
[74] 尹春萍,吴继洲.泽泻及其活性成分免疫调节作用研究进展[J].中草药,2001,32(12):1132.
[75] 曾正渝.兰作平.肉桂的研究现状及应用进展[J].现代医药卫生.2007,23(1):59 60.
[76] 蒋淑君,等.糖皮质激素对HPAA的影响及仙灵脾的调整作用[J].滨州医学院学报,2004,(27)2:87 90.
[77] 牛效清,王振,等.仙灵脾对慢性肾衰患者细胞免疫功能的影响[J].黑龙江医药科学,2002,25(5):44.
[78] 孙劲秋,何学红.肾性贫血机制探述[J].辽宁中医学院学报,2005,7(5):515 517.
[79] 李更生,等.地黄化学成分与药理研究进展[J].国外医学中医中药分册,2004,26(2):74 79.
[80] 祝晓玲 ,等.黄芪注射液影响贫血小鼠粒单系、红系造血及作用机制的探讨[J].中国中西医急救杂志,2001,8(5):284 286.
[81] 王艳萍,等.川芎嗪药理作用的研究进展[J].药品评价,2006,3(2):144 147.
[82] 邓家刚,等.鸡血藤药效及作用机理研究进展[J].广西中医药,2006,29(6):1 3.
[83] 高瑞兰,等.三七皂甙对造血细胞GATA 1和GATA 2转录调控蛋白的诱导作用[J].中华血液病杂志,2004,25(5):281 284.
[1] 张天,陈以平.实用中医肾病学(M).上海:上海中医学院版社 1990.
[2] 杨崇华.祖国医学对尿毒症的认识初探[J].中医研究,1996,9(4):3
[3] 郭恩绵.慢性肾功能衰竭的中医诊断命名及辨证论治之我见[J].实用中医内科学杂志,1988,(2):162.
[4] 时振声.慢性肾功能不全的中医治疗体会[J].吉林中医杂志,1989,(5):5.
[5] 高峻钰.慢性肾功能衰竭中医证治进展[J].中医杂志,1995,36(9):562.
[6] 傅文录.慢性肾功能衰竭中医治则新论[J].新中医 l995(2):6.
[7] 孙万森,等.益肾降脂片治疗慢性肾功能衰竭的临床和实验研究[J].中国中医药科技,1996,3(5):11.
[8] 张佩青,等.补脾肾泻湿浊解毒活血法治疗慢性肾功能衰竭的临床研究[J].中国中医药科技,1994,1(1):9.
[9] 郭兆安.祛毒散治疗慢性肾功能衰竭31例临床观察[J].中国中西医结合杂志,1995.15(11):679.
[10] 魏练波,等.慢性肾功能衰竭并发症的中医治疗[J].中医杂志,1997,38(4):222.
[11] 彭建中,扬连柱.赵绍琴临证验案精选(M).北京:学苑出版杜,1996,208 220.
[12] 赵动,等.肾衰系列方治疗慢性肾功能衰竭的体会[J].中医杂志,1994,35(3):143.
[13] 王文春.化瘀解毒法治疗慢性肾炎肾功能衰竭的临床体会[J].河南中医,1994,(5):297.
[14] 邓乐巧.以三焦气化辨治慢性肾功能衰竭14例[J].云南中医杂志,1994,15(2):7.
[15] 傅晓骏.谈“瘀浊蕴毒”与慢性肾衰竭[J].中国中西医结合肾病杂志,2002,3(5):293.
[16] 沈庆法.慢性肾功能衰竭的中医认识和临床研究[J].上海中医药杂志,2000,34(3):42 44.
[17] 栾雷.慢性肾衰关乎少阳阳明[J].辽宁中医杂志,2005,32(2):112 l13.
[18] 刘丙欣.运用络病理论辨治慢性肾功能衰竭解析[J].中医药学刊,2005,23(3):505 506.
[19] 谢帮军,张军锋,石景亮.从三焦辨治肾病临床经验[J].四川中医,2005,23(2):1 2.
[20] 曾莉.洪钦国教授治疗慢性肾功能不全经验介绍[J].新中医,2006:38(4):13 14.
[21] 傅文录.慢性肾衰中医多级辨证思想与方法[J].新中医,1999,31(6):19.
[22] 王淑渡,等.保元强肾I号片对慢性肾功能衰竭血浆及尿SOD、MDA的影响[J].浙江中西医结合杂志,1997,7(2):67.
[23] 沈维增,李俊彪,伍新林,等.泄浊汤对慢性肾衰竭患者脂质代谢及肾功能的影响[J].中国中西医结合肾病杂志,2004,5(3):166 168.
[24] 刘延东,吴世杰.加减八珍汤治疗慢性肾功能衰竭40例疗效观察[J].中国中医药科技,2004,l1(3):178 179.
[25] 周富明.慢性肾衰辨治五法[J].浙江中医杂志,2005,2:74 75.
[26] 薛红等.杜仲补腰合剂改善慢性肾功能不全的实验研究[J].河北中医药学报,2004,19(3):1 4.
[27] 宁越峰,杨柳竹,等.加味八珍汤治疗慢性肾功能不全患者营养不良[J].中国煤炭工业医学杂志,2002,5(7):729.
[28] 朱玮华.温补脾肾、通阳泄浊法治疗慢性肾功能衰竭一得[J].中国临床医生,2006,34(4):47.
[29] 何灵芝. 补阳还五汤治疗肾病举隅[J].广西中医药,2005,28(6):34.
[30] 胡臻.升阳排毒汤治疗慢性肾功能不全疗效观察[J].浙江中西医结合杂志,2002,l2(8): 478.
[31] 朱洪丽.理脾法治疗慢性肾功能不全体会[J].实用中医药杂志,2004,20(11):655.
[32] 许钟镐.活血化瘀中药复方延缓慢性肾功能不全的实验研究[J]. 延边大学医学杂志, 2000 , 23(1): 44-46.
[33] 冯文学.大黄治疗慢性肾功能不全25例的疗效分析[J]. 河南医药信息 2000,2(8): 57.
[34] 刘学耀,洪钦国.尿毒清胶囊治疗45例慢性肾衰疗效分析[J].中医药学刊,2004,22(4):687 688.
[35] 李文红,王淑君.肾衰降浊丸治疗慢性肾功能不全50例[J].实用中医内科杂志,2005,19(2):165.
[36] 李贵明,常连刚,孙晓燕,等.黄虎肾衰散在慢性肾衰竭中的应用[J].中国中西医结合杂志,2005,6(1):48 49.
[37] 詹永力,等.和解法对延缓慢性肾功能衰竭病程进展的研究[J].中国中西医结合杂志,1995,15(2):71.
[38] 冯松杰.大黄鹰虫丸治疗血液透析患者脂质代谢异常22例[J].辽宁中医杂志,1996,23(8):368.
[39] 刘文军,等.中药尿毒净腔囊治疗慢性肾功能衰竭的近期疗效察[J].实用中西医结合杂志,1995(8):555.
[40] 刘慰祖,等.中医药对慢性肾功能衰竭患者脂质代谢的影响[J].上海中医药杂志,1995,(7):15.
[41] 夏海岩.扶正降浊汤为主治疗慢性肾功能不全30例[J].辽宁中医药学报,2000,,2(4)::292.
[42] 金翠萍.参芪地黄汤联合黄连温胆汤加生大黄治疗慢性肾功能不全3l例[J].华北煤炭医学院学报,2004:6(3):341.
[43] 吴兆东,朱海龙,王国斌,等.大黄廑虫丸联合金水宝胶囊治疗慢性肾功能衰竭53例[J].中国中医药信息杂志,2005,12(2):68 69.
[44] 胡筱娟.尿毒宝胶囊治疗慢性肾功能不全32例[J].陕西中医,2005,26(4):311 312.
[45] 程仁权.大黄在慢性肾衰中的应用[J ]. 中医药学报,1998,26 (6):49 50.
[46] 宁远英.大黄素对人肾成纤维细胞增殖的影响[J ]. 中西医结合杂志,2000,20 (2):105.
[47] 魏向阳.大黄延缓慢性肾功能衰竭机制的研究进展[J]. 现代中医药,2003,(3):58 59.
[48] 肖炜,邓虹珠,马云.大黄治疗慢性肾功能衰竭的临床与实验研究概述[J].中国中药杂志,,2002,27(4):241 242.
[49] 齐家友,王海燕,王叔咸.黄芪和当归治疗3种不同病理类型肾炎的实验研究[J].中华内科杂志,1996,35(4):222.
[50] 崔明姬, 徐学明.慢性肾功能不全患者血浆神经肽Y变化及黄芪对其影响的研究[J].白求恩医科大学学报,2001,27 (2):164 165.
[51] 周钦,陈雪梅,高渝军.大剂量黄芪对慢性肾功能不全患者血、尿降钙素基因相关肽的影响[J]. 北京中医药大学学报,,2000,23 (12):59 60.
[52] 王莹,李振华.黄芪对慢性肾功能不全患者抗氧化酶和一氧化氮的影响[J].哈尔滨医药,2002,22 (6):5 6.
[53] 王本祥.现代中药药理学(M).天津:天津科学技术出版社,1999:883 884.
[54] 李洪清,徐学明.丹参对慢性肾功能不全患者血清白细胞介素 6和肿瘤坏死因子的影响[J].临床内科杂志,2002,19 (6):470 471.
[55] 周晓萍,袁红玲.丹参注射液在慢性肾功能不全患者中的应用[J].职业与健康,2003,19 (4):135 136.
[56] 黄道勤,赖建生,夏强,等.丹参注射液保护肾缺血 再灌注损伤的实验研究[J]. 海南医学,2004,15 ( 7 ):116 114.
[57] 陈英.三七总苷的药理研究及临床应用进展[ J ]. 广西医学,1998,20 (6):1109 1112.
[58] 叶任高.内科学(M).北京:人民卫生出版社,2002,570.
[59] 杜军.三七止血活血机理研究Ⅰ:不同剂量的三七对小鼠凝血系统的作用[J ].中药药理与临床, 1995:111 (5):25 28.
[60] 陈江斌,许家璃,江洪,等.三七总皂苷对冠心病患者过氧化脂质及纤维蛋白溶酶原激活物的影响[J ].中国新药杂志, 2000, 9 (11):781 782.
[61] 周晓霞,苏佩清,杨鹤梅,等.三七总皂苷对人高脂血清诱发的胎儿血管平滑肌细胞增殖的抑制作用[J ]. 中国动脉硬化杂志,,2000,8(1):43 45.
[62] 曾青,陈吉球,黄勤等.三七总皂苷对血清及肺组织血管紧张素转换酶的影响[J ].广西医科大学学报,1998,15 (3):36 38.
[63] 韦颖,樊均明,潘丽萍.三七总苷对人肾成纤维细胞的影响[J ].中国中西医结合杂志,2002,22 (1):47 49.
[64] 王莉,王丽,万晓京,等.黄葵胶囊治疗慢性肾脏疾病的临床观察[J].中医药信息,2002,19 (1):36 37.
[65] 傅余芹.冬虫夏草制剂对慢性肾功能不全患者T细胞亚群的影响[J].深圳中西医结合杂志,2003,13 ( 1 ):21 26.
[66] 赵继红.百令胶囊对慢性肾功能不全患者脂代谢水平的影响[J].天津中医,2002,19 (5):9.
[67] 吕凤岩.包醛氧淀粉胶囊联合冬虫夏草制剂治疗慢性肾衰竭的临床观察[J].中国中西医结合肾病杂志,2004,5(9):525 526.
[68] 邓跃毅,陈以平,贺学林,等.冬虫夏草制剂延缓慢性肾衰竭的机理研究[J].中国中西医结合杂志,2001,2(7):381 383.
[69] 张盛光,熊国良,阳硗,等.益气补肾冲剂治疗慢性肾功不全的初步临床及实验研究[J].中国中西医结合杂志,l992:12(6):335.
[70] 张琪. 张琪临床经验辑要[M ]. 北京: 中国医药科技出版社,1999,80 80.
[71] 姜桂芹,韩学忠.归脾汤加减治疗慢性肾衰贫血的临证体会[J ]. 中国中西医结合肾病杂志,2003,4 (4):231 232.
[72] 孙万森,刘锐. 治疗慢性肾衰经验探要[J ]. 陕西中医,2000,(5) :212 213.
[73] 骆常义,龚去非.治疗慢性肾衰经验[J ]. 实用中医药杂志.2000,16(2):36 37.
[74] 朱冬云,蓝华生.治疗慢性肾衰经验[J ]. 河北中医,2000,22 (10):746 747.
[75] 姜桂芹,韩学忠.归脾汤加减治疗慢性肾衰贫血的临证体会[J ].中国中西医结合肾病杂志,2003,4 (4):231 232.
[76] 段淑兰,陈小仙,蒋鹏.中药为主治疗慢性肾功能不全40例临床观察[J]. 河南中医,2004,5 (24):36 37.
[77] 庞莉,张小斌,张渭.从瘀辨治慢性肾功能不全临床观察[J].现代中医药,2003,(1):31 32.
[78] 李淑菊,张佩青,黄彦彬,等.肾衰胶囊延缓失代偿期慢性肾功能衰竭进展39例临床观察[J].中医杂志,2005,46(5):348 350.
[79] 王少华,陈静,付强.肾衰胶囊对慢性肾功能衰竭大鼠细胞凋亡的影响[J].中药材,2004,27(3):195 197.
[80] 王少华,张晶瑜,张春梅.肾衰胶囊对肾衰大鼠肾功能及血NO、TNF2α的影响[J].中成药,2004,26(1):54 56.
[81] 张秀萍等. 尿毒清颗粒治疗慢性肾衰竭临床分析[J].中华现代中西医杂志.2005:3(18):1683 1684.
[82] 库保庆,高智.补阳还五汤治疗慢性肾衰竭的临床研究[J].临床肾病杂志.2007,7(2):74
[83] 郭兆安. 清氮汤灌肠治疗CRF43例[J].中国中西医结合志.1996,18(9):564.
[84] 来永兰,孙文芹,等. 祛浊温阳汤灌肠治疗慢性肾功能不全临床观察[J].中国中西医结合急救杂志,2003,10(4):247 248.
[85] 王其丽,张正勇.中药保留灌肠治疗肾功能不全56例疗效观察[J].中华中医药杂志,2005,20(8):511.
[86] 刘文合,施绍用,等. 中药灌肠治疗慢性肾功能不全疗效观察[J].中华医学实践志,2005,5(6):651 652.
[87] 张伟君,彭建华,等. 复方大黄汤灌肠治疗慢性肾功能不全临床疗效观察[J].中华现代中医学杂志,2006,2(3):215 216.
[88] 梁淼,胡亚丹,等. 中药保留灌肠治疗糖尿病肾病肾功能不全临床观察[J].实用中医内科杂志,2006,20(6):663.
[89] 王艳秋.灌肠治疗慢性肾功能不全32例疗效观察[J].局解手术学杂志,2007,16(3):188 189.